
19/07/2025
OKYO Pharma CEO details positive results from Phase 2 urcosimod trial - ICYMI: OKYO Pharma Ltd (NASDAQ:OKYO) CEO Gary Jacob talked with Proactive about the recently announced topline data from the company’s Phase 2 trial evaluating urcosimod in patients with neuropathic corneal pain.
Jacob explained that neuropathic corneal pain is a severe nerve pain condition without any FDA-approved treatments, describing it as “like having a spinal cord injury in your eye.”
The trial was a randomized, placebo-controlled study involving 48 patients. OKYO Pharma used confocal microscopy to ensure participants truly suffered from neuropathic pain rather than inflammatory causes.
The company decided to halt the study early after 17 patients completed 12 weeks of treatment due to significant reductions in pain observed in those receiving urcosimod topically.
Proactive: All right, welcome back inside our Proactive newsroom. And joining me now is Gary Jacob. He is the CEO of OKYO Pharma. And Gary, it’s great to see you again. How are you?
Gary Jacob: Same here. A...
OKYO Pharma Ltd (NASDAQ:OKYO) CEO Gary Jacob talked with Proactive about the recently announced topline data from the company’s Phase 2 trial evaluating...